JPRN-UMIN000013945Recruiting未知
TS-1+ Oxaliplatin+ Bevacizumab therapy in consideration of OPTIMOX design for metastatic colorectal cancer - SABMOX study
Sapporo Medical University School of Medicine0 sites45 target enrollmentStarted: May 13, 2014Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 45
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1.Need to drain malignant fluid. 2.With a history of allergic response to Fluorouracil or Levofolinate calcium or Platinium. 3.Pregnant or lactating women or women of childbearing potential. 4.Uncontrolled infection. 5.Evidence of interstinal lung disease, or pulmonary fibrosis. 6.Clinically significant (i.e. active) cardiovascular disease or past or current history (within the last 1 year) of myocardial infarction. 7.Uncontrollable ulcer indigestive tract. 8.Radiological evidence of CNS metastases or brain cancer. 9.Complication of cerebrovascular disease or symptoms within 1 year. 10.Any surgical treatments within 4 weeks. 11.Administering antithrombotic drug within 10 days. Need to administrate or having anti-platelets therapy 12.Multiple primary cancers within 5 years. 13.Other conditions not suitable for this study.
Investigators
Similar Trials
Not yet recruiting
Phase 1
A phaseI trial of S-1 Oxaliplatin and Bevacizumab in combination with Radiotherapy for Neozdjuvant Therapy of Locally advanced lower rectal cancerResectable lower rectal cancerJPRN-UMIN000006937Tokushima University Hospital Dept. of Digestive and Pediatric Surgery15
Completed
Phase 2
Treatment using Oxaliplatin and S-1 Adjuvant chemotherapy for Stage III gastric cancer trialGastric cancerJPRN-UMIN000025824Department of Surgery, Kochi Medical School75
Completed
Phase 1
Combination chemotherapy of TS-1, oxaliplatin and irinotecan (TIROX) for unresectable gastric cancer; a phase I studygastric cancerJPRN-UMIN000030482Osaka Medical College Hospital18
Recruiting
Phase 1
Phase I/II study of TS-1 / Oxaliplatin / Cetuximab / Radiation for KRAS wild type locally advanced and recurrent rectal cancer.advanced and recurrent rectal CancerJPRN-UMIN000006304Graduate School of Medicine, Osaka Univesity31
Completed
Phase 2
S-1 plus Oxaliplatin combination chemotherapy in a stop-and-go fashion for metastatic colorectal cancerJPRN-UMIN000004086Yodogawa Christian Hospital40